Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis - Feng, J; Dai, W; Mao, Y (J Exp Clin Cancer Res, 2020)